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Athletics is a highly diverse sport that contains a set of disciplines grouped into jumps,
throws, races of varying distances, and combined events. From a physiological stand-
point, the physical capabilities linked to success are quite different among
disciplines, with varying involvements of muscle strength, muscle power, and
endurance. Thus, the use of banned substances in athletics might be dictated by phys-
ical dimensions of each discipline. Thus, the aim of this investigation was to
analyse the number and distribution of adverse analytical findings per drug class in
athletic disciplines. The data included in this investigation were gathered from the
Anti-Doping Testing Figure Report made available by the World Anti-Doping Agency
(from 2016 to 2018). Interestingly, there were no differences in the frequency of
adverse findings (overall,0.95%, range from 0.77 to 1.70%) among disciplines
despite long distance runners having the highest number of samples analysed per year
(9812 samples/year). Sprinters and throwers presented abnormally high
proportions of adverse analytical findings within the group of anabolic agents
(p < 0.01); middle- and long-distance runners presented atypically high proportions of
findings related to peptide hormones and growth factors (p < 0.01); racewalkers pres-
ented atypically high proportions of banned diuretics and masking agents (p = 0.05).
These results suggest that the proportion of athletes that are using banned substances
is similar among the different disciplines of athletics. However, there are substantial
differences in the class of drugs more commonly used in each discipline. This informa-
tion can be used to effectively enhance anti-doping testing protocols in athletics.
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1 | INTRODUCTION
Athletics is a highly diverse sport that contains a set of disciplines
grouped into jumps, throws, races of different distances, and
combined events. From a physiological standpoint, the physical
capabilities linked to success in athletics are different among
disciplines—with varying contributions of muscle strength, muscle
power, and endurance.1,2 On one hand, jumps, throws, combined
events, and sprint races up to 400 m require high values of speed and
muscle power while body characteristics such as height or elevated
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body mass may have a positive contribution on some disciplines such
as shot put and the hammer throw. Conversely, performance in
middle- and long-distance running races and racewalking is based on
the combination of high maximal oxygen uptake, running speed at lac-
tate threshold, and running/racewalking economy. Low body bass
may also be beneficial for these physiological determinants and is
usually a key anthropometric objective in long distance athletes. With
a few exceptions, elite athletes are only capable at achieving records
within their own discipline, signifying the unique performance charac-
teristics of each discipline. In fact, the evolution of track and field
records in the last century has been uneven.3,4 It has been speculated
that the use of banned substances might have contributed to the
atypical achievements found in some disciplines at very specific
moments.5 In this regard, it has been previously speculated that the
use of banned substances in each track and field discipline might be
dictated by the discipline's physiological dimensions and performance
determinants,6 but to date, this has not been properly confirmed with
real and objective data.
An adverse analytical finding indicates the presence of prohibited
substances in a particular sample obtained during a doping control
test and measured by a laboratory accredited by the World Anti-
Doping Agency (WADA). Previous research7 has revealed that the
prevalence of adverse analytical findings in athletics is around 1.6%,
which has been kept relatively constant since 2003. Despite having
the highest number of doping control tests conducted each year,7
athletics has one of the lowest proportions of adverse analytical
findings among individual sports. However, the prevalence of doping
has been estimated to be up to 43.6% in World Championships in
athletics by using surveys with the randomized response technique.8
The discrepancy in the estimated prevalence of doping by survey-
based investigations and the proportion of adverse analytical findings
may be associated to the different methodologies used to collect the
information. Nevertheless, it suggests that the current anti-doping
systems has several limitations to accurately trace the use of banned
substances and methods. Specifically, the limited analytical capability
of WADA-accredited laboratories, the short detection window for
some banned drugs, and the economic costs of testing athletes
several times during the season produce that some cheaters remain
undetected by the current system of doping control.9 Despite these
limitations, the analysis of the results of doping tests is an objective
and robust method that allow to understand trends in the abuse of
substances within a particular sport.7
Overall, anabolic agents represent the most commonly found
adverse drug finding of in athletics (when analysing all disciplines
together as a unique sport), followed by peptide hormones and
stimulants.10 Interestingly, the concentration of these substances is
higher than the concentration found in other individual and team
sports.10 However, it is likely that the prevalence of adverse analytical
findings across drug classes is different among all track and field
athletic disciplines, as the physiological determinants are highly differ-
ent among disciplines. Obtaining more information about the most
commonly used substances in each athletic discipline might be the key
to plan more comprehensive anti-doping policies. This would entail
the establishment of in- and out-of-competition doping testing on ath-
letes by specifically searching for substances habitually used in each
discipline. Thus, the aim of this investigation was to analyse the num-
ber and distribution of adverse analytical findings per drug class in ath-
letics disciplines using data from the WADA-accredited laboratories.
2 | METHODS
For this study, we used the Testing Figures Reports made available
annually by WADA.11 These reports include information from all
WADA-accredited laboratories about the number of analysed samples
and adverse findings per drug class. In 2014, WADA published this
information for track and field for the first time. This information was
further stratified by each track and field discipline in the last three
reports from 2016–2018. For this reason, this investigation
represents an analysis of WADA's Testing Figure Reports from 2016
to 2018.
In these reports, the adverse findings are categorised by the
group of substances included in the WADA List of Banned
Substances.12 Substances “prohibited at all times” (i.e., in- and out-
of-competition) include (a) anabolic agents, (b) peptide hormones
and growth factors, (c) β-2 agonists, (d) hormone and metabolic
modulators, and (e) diuretics and masking agents. Substances that
are prohibited only during competitions include (f) stimulants,
(g) narcotics, (h) cannabinoids, and (i) glucocorticoids. In this
investigation, we have not analysed data about prohibited methods.
The current investigation presents an ad hoc analysis of the
number of doping tests conducted and of the number of adverse
analytical findings per drug class in athletic disciplines. According
to the athletics programme for Olympic competitions (track, field,
and road events), track and field athletes are categorized into eight
different groups: (1) sprinters (sprint races up to 400 m), (2) middle-
distance runners (800 m and 1500 m), (3) long-distance runners
(5000 m and 10,000 m), (4) road runners (marathon), (5) race
walkers (20 km and 50 km), (6) jumpers (long jump, triple jump,
high jump, and pole vault), (7) combined events (heptathlon and
decathlon), and (8) throwers (shot put, discus throw, hammer
throw, and javelin throw).
From the data included in the Testing Figure Reports, we
excluded samples that had insufficient information for the purposes of
the study or were labelled as “Athletics” (5176 data in 2016, 447 data
in 2017, and 186 data in 2018) since it was impossible to categorize
the data into any of the above mentioned athletic disciplines.
2.1 | Statistical analysis
The data were electronically extracted from the Testing
Figures Reports and entered into a database designed for the pur-
poses of this research. The data were extracted by one author (MAN)
using a spreadsheet (Excel 2016, Microsoft Office, WA, USA) and
were then checked for accuracy by another author (JDC). After, mean
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and standard deviation (SD) from each track and field athletic
discipline were obtained by using the data of the last three reports
(2016–2018). Afterwards, the proportion of adverse analytical find-
ings in each discipline was calculated for each year by dividing the
number of adverse analytical findings by the number of samples
within each track and field discipline. The proportion of analytical
findings per drug class was calculated by dividing the number of
adverse findings in each drug category by the total number of adverse
findings within each track and field discipline.
Kruskal–Wallis tests were used to detect differences in the
number of samples analysed and in the proportion of adverse analyti-
cal findings among disciplines. The differences in the distribution of
adverse analytical findings per drug class were tested with crosstabs
and χ2 tests, including adjusted standardised residuals. A discipline
was considered to have an atypical distribution of adverse findings
per drug class when the proportion of any drug class was below or
above the critical value of Z (i.e., 1.96). This was based on the a priori
assumption that all disciplines would have a similar distribution in
the adverse findings per drug class. The data were analysed with
the statistical package SPSS v 24.0 (SPSS Inc., Chicago, IL). The
significance level was set at p < 0.05.
3 | RESULTS
A total of 87,380 doping control tests were taken and analysed
for athletics from 2016 to 2017. Figure 1 contains information
about the number of samples analysed per year in each discipline.
The statistical analysis revealed a significant difference in the num-
ber of samples analysed among disciplines (K = 21.52; p < 0.01).
The number of samples analysed in long-distance runners and
sprinters was higher than in athletes of combined events, road
runners, and racewalkers (p < 0.05). The samples analysed in throw-
ing and jumping events were also higher than in racewalking
(p < 0.05).
The ANOVA analysis revealed no significant differences in the
proportion of adverse analytical findings among disciplines
(F = 8.91; p = 0.26). Overall, the frequency of adverse analytical
findings in most disciplines was below 1.0%. Only road runners
(1.7 ± 0.2%) and long-distance runners (1.1 ± 0.2%) had an average
that lied beyond this threshold. A detailed analysis of the number of
adverse findings per year in each discipline is included in Table 1.
However, to allow for a better comparison that eliminates the effect
of the different number of samples in each discipline, Figure 2
F IGURE 1 (A) Number of
samples analysed and
(B) percentage of adverse
analytical findings in track and
field disciplines. Each discipline's
data from 2016 to 2018 are
represented by mean ± SD. (*)
Statistically significant difference
from combined events, road
runners, and racewalkers at
p < 0.05. (†) Statistically
significant difference from
racewalking at p < 0.05
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contains the frequency of adverse analytical findings per drug cate-
gory in each discipline. The proportion of anabolic agents found in
the samples of sprinters and throwers was higher than expected
(p < 0.01) while being lower than expected in athletes of combined
events. Peptide hormones and growth factors were more commonly
found in middle- and long-distance runners when compared with
the distribution of the remaining disciplines (p < 0.01). Sprinters,
throwers, and jumpers presented an abnormally low frequency of
peptide hormones and growth factors. Long-distance runners had a
higher than expected proportion of β2-agonists (p < 0.01). Sprinters,
jumpers, and middle-distance runners presented higher than
expected frequencies of hormone and metabolic modulators
(p < 0.01). Interestingly, the proportion of diuretics and masking
agents was higher than expected in racewalkers (p = 0.05). The pro-
portions of stimulants and narcotics found in doping control test
samples were similar in all disciplines. The frequency of cannabi-
noids was higher than expected in jumpers (p < 0.01), and the pro-
portion of glucocorticoids was higher in road runners and long-
distance runners (p < 0.01).
4 | DISCUSSION
To understand the differences in doping behaviours among athletic
disciplines, the goal of this investigation was to analyse the number
and distribution of adverse analytical findings per drug class in track
and field disciplines. The main outcomes of this investigation were
(a) long distance runners and sprinters had the highest number of
samples analysed with more than 6000 doping control tests
conducted each year. On the other hand, race walkers and road
runners had less than 1000 doping control tests per year; (b) there
were no statistical differences in the proportion of adverse analytical
findings among the different disciplines. However, road runners had
the highest proportion of adverse analytical findings with 1.7 ± 0.2%
(Figure 1); and (c) the number and proportion of banned substances
detected in anti-doping control tests were different depending on the
track and field discipline (Figure 2) with sprinters and throwers having
a higher proportion of anabolic agents and middle- and long-distance
runners having a higher proportion of peptide hormones and growth
factors. These results suggest that the proportion of athletes using
banned substances is relatively even in all track and field disciplines,
but the type of banned substances used in each discipline
greatly depends on the physiological and performance determinants
of each discipline.
Most of the track and field disciplines had a proportion of adverse
analytical findings close to 1.0% (Figure 1). However, road runners
had the highest proportion of adverse analytical findings among all
disciplines during the examined period, while they had an abnormal
proportion of glucocorticoids. Interestingly, road runners have several
characteristics that might predispose them to cheating behaviours—at
least in comparison with the remaining disciplines. First, due to the
length of most road races and its physiological challenges, road
runners only compete as marathoners once or twice per year. This
imposes a higher pressure on them as they have less opportunities to
demonstrate high performance than track and field athletes
do. Second, road runners usually compete in mass events, such as the
World Marathon Majors, that award large sums of prize money. Thus,
the high media attention and likelihood of winning prize money may
be another factor in explaining the slightly higher percentage of
adverse analytical findings in road runners.13 In fact, the Athletics
F IGURE 2 Distribution of adverse analytical findings per category of banned substances in each track and field athletic discipline. The data
are characterized by mean frequency per year for each discipline from 2016 to 2018. SD has been removed for clarity
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Integrity Unit (AIU), an independent organization that manages threats
to the integrity of track and field, has announced a new initiative to
counteract doping misconducts in professional marathon runners.14
This is because a large majority of marathon competitions do not per-
form doping control tests, which would explain the low number of
conducted tests in this discipline (Figure 1). The 2019 Annual Report
of AIU15 indicates that 49% of samples obtained under the umbrella
of this organization corresponded to long distance runners. In addi-
tion, the number of blood samples collected was almost equal to the
number of urine samples (5426 vs. 5459, respectively), while 43% of
athletes competing in the World Championship of Doha 2019 had
undergone three or more out-of-competition testing. Last, they
reported a total of 13 Adverse Passport Findings. All these data con-
firm the AIU has focus its own testing efforts in a much more targeted
manner, while considering the haematological module of the Athlete
Biological Passport is of upmost importance to organize target tests.
Still, road running is below the proportion of adverse analytical find-
ings found in other disciplines like cycling, weightlifting, and rowing,7
but national and international anti-doping authorities associated to
athletics should increase the anti-doping pressure on road races.
Between 2014 and 2017, anabolic agents were the most com-
monly found prohibited substance in track and field doping tests.10
Moreover, anabolic agents were the most frequent category of
prohibited substances when merging the data of the substances
detected in doping control tests of all Olympic sports.16 Both findings
manifests the need for more effective policies to reduce the use of
anabolic agents in sport. The current analysis reveals that anabolic
agents were the most commonly used prohibited substance in
sprinters and throwers (Figure 2). Although the disciplines integrated
into sprint races and throwing events possess differences in their
physical dimensions, all share the need of formidable values of muscle
power for succeeding.1 Because of this need, anabolic agents might
be used to increase muscle mass, which would produce enhanced
values of muscle power through enhanced application of muscle
strength.17 World Athletics considers serum testosterone concentra-
tion as the most significant factor in influencing athletic performance
in short-term track and field disciplines.18 For this reason, World Ath-
letics issued new eligibility requirements for females in track events
between 400 m and one mile to avoid the potential advantage that
hyperandrogenic women may have in these types of competitions.19
This information points towards the great capacity of anti-doping
laboratories to detect anabolic agents and the usefulness of the
steroidal module of the Athlete Biological Passport in high-
performance sprinters, throwers, and other track and field athletic
disciplines in which success primarily depends on muscle power. To
this regard, the number of adverse analytical findings detected by
using isotope ratio mass spectrometry has changed from 72 in 2014
to 159 in 2017.
Interestingly, jumping and combined events also share the need
for high values of muscle power, but the proportion of anabolic agents
is lower. In the case of jumpers, they had an abnormal proportion of
hormone and metabolic modulators (Figure 2). Within the group
of hormone and metabolic modulators lies several synthetic
compounds, which act by modulating various endogenous hormonal
pathways and muscle-specific transduction pathways. In most cases,
the aim of such modulators is to enhance non-steroidal anabolism,
although it is has been found that some of them may counteract the
unwanted side effects of anabolic androgenic steroid administration.6
In the case of combined events, there was a high proportion of gluco-
corticoids, likely due to the use of these banned substances to
treat the consequences in form of injury and pain induced by the
extreme physical demands of this discipline. Although the high use of
glucocorticoids has previously been reported in other elite sports—
where overuse is a particular concern20—anti-doping organizations
should make an effort to reduce the use of this group of substances in
combined events.
Peptide hormones and growth factors were more commonly
found in middle- and long-distance runners. This drug class contains
erythropoietin-receptor agonists, hypoxia-inducible factor activating
agents, and innate repair receptor agonists, all of which have a
potent capacity to increase erythropoiesis and red blood cell
concentration in the blood. In middle- and long-distance race
events, blood oxygen carrying capacity is an essential factor for per-
formance. Thus, several peptide hormones may help to increase
muscle oxygen supply, ultimately boosting performance.21 Growth
factors—such as growth hormone—may help to reduce body fat and
enhance tissue-repairing effects on the musculoskeletal system,
which may be performance factors for middle- and long-distance
runners. Interestingly, the presence of adverse findings due to
peptide hormones and growth factors in disciplines whose success
primarily depends on muscle power was small. Together, these
outcomes suggest that the search for this class of drugs in doping
control tests may primarily be focused on track and field disciplines
with an endurance component.
At the same time, long distance runners had an atypical propor-
tion of β2-agonists. β2-agonists are commonly used as bronchodila-
tors in the treatment of asthma, which is the most common medical
condition in elite-level athletes.22 In the last few years, the perception
that asthma medication may enhance sports performance has created
a negative stigma towards athletes with asthma.23 WADA currently
allows the therapeutic use of salbutamol, formoterol, and salmeterol.
These substances are only considered as an adverse finding when
they surpass a certain threshold.24 Although the majority of studies
have demonstrated limited effects of inhaled β2-agonists on aerobic
exercise performance,25 short-term oral administration of salbutamol
has been shown to significantly improve submaximal time to exhaus-
tion in non-asthmatic elite athletes.26 Anti-doping authorities should
study the motives behind the high proportion of findings related to
β2-agonists in endurance athletes and harden the criteria to grant
therapeutic use exemptions if necessary.27
Racewalkers had a high proportion of diuretics and masking
agents. Despite diuretics not directly producing a clear benefit on
physical performance, they can be used to mask the administration of
other doping agents by reducing their concentration in urine through
increased urine volume.28 The authors hold the opinion that the use
of diuretics may not entail a potential benefit for racewalking races
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since these events have a long duration and the hypohydration pro-
duced by these substances may be negative for performance.29 A
more thoughtful analysis should be made to determine why
racewalkers may use diuretics and other masking agents.
The current analysis has some limitations that should be
considered when drawing conclusions about the use of banned sub-
stances in track and field disciplines. First, the current investigation
includes an analysis of the adverse analytical findings obtained by the
system of doping control tests in athletics. However, it has been pre-
viously proposed that the current anti-doping system has several
flaws that allow that some athletes using banned substances remain
undetected.9 In fact, it has been suggested that the probability of
detecting a cheater is only of 33% when the athlete is tested 12 times
per year and it may be needed up to 50 tests per athlete to detect
100% of doping.30 It is probable that the analysis of detected sub-
stances included in this investigation only represents a portion of the
total amount of banned substances used in athletics. Hence, the study
of the statistics of adverse analytical findings should not be used as
the only strategy to predict doping behaviours in athletics. Second, an
adverse analytical finding does not always result in an anti-doping rule
violation. All adverse findings are subjected to a results management
process by World Athletics or by national anti-doping organisations.
Thus, some of the adverse analytical findings reported here may not
end in an anti-doping rule violation and subsequent sanction. Second,
the current study did not include an analysis about the chemical and
physical manipulation of blood and blood components. Further inves-
tigations should be designed to ascertain differences in the use of
banned methods among sport disciplines. Third, data might have been
included in two or more disciplines as athletes may have competed in
two or more different disciplines. In any case, these data would reflect
the doping behaviour of the athlete in each track and field discipline.
Lastly, despite the interest of WADA to accurately monitor the
patterns of doping misbehaviours in all sports and its disciplines, the
data reported by the laboratories still have a considerable amount of
samples categorized as “Athletics,” likely due to the improper catego-
rization of information of the doping control officer during testing.
Although the categorization of track and field disciplines in the doping
control forms has improved in the last few years, WADA must empha-
size correct classifications of track and field disciplines on their doping
control documents to avoid samples merely being classified as
“Athletics.” Despite these limitations, the analysis included in this
investigation is sound at understanding the main substances used in
each track and field discipline.
In summary, the analysis of WADA's Testing Figures Reports
suggests that the prohibited substances used as doping agents might
be substantially different depending on the particularities of each
track and field discipline. The outcomes of this research indicate the
need for more discipline-specific anti-doping strategies in track and
field to produce a more efficient and cost-effective process. To this
regard, the haematological and steroidal modules of the Athlete
Biological Passport become as key tools for detecting the use of
banned substances and methods and to enhance the information to
decide about targeted testing. The information included in this
investigation may be useful at increasing the efficacy of disciplinary
and deterrent policies or informing athletes about the potential side
effects of the most commonly used substances in their disciplines.
However, anti-doping authorities should be aware that doping mis-
conducts are in constant change while the analytical capacity of the
laboratories may be not enough to detect the use of some substances
in microdoses.
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